Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.
Carbios raises €141m to boost enzymatic PET recycling
Latest NewsIn an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.
EG 427 expands Series A closing to €18m
Latest NewsParis-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.
Tasteful plant protein
BackgroundConventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
New President for Flash Therapeutics
AppointmentsToulouse-based Flash Therapeutics has appointed Jerome Bedier as its new President.
Seed money for unique topical hair growth inducer
Latest NewsMallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.
Evotec earns US$40m in global licence deal with BMS
Latest NewsGerman CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
Nanobiotix SA licences NBTXR3 to J&J
Latest NewsParis-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Latest NewsExeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.
ASEBIO commenting on EU GMO proposal
OpinionDutch go first: pre-approval tastings of cultivated meat & seafood in the Netherlands
Latest NewsIt is just announced that it will soon be possible to taste farmed meat and seafood in the Netherlands under controlled conditions. The Dutch government, in collaboration with cultured meat producers Meatable and Mosa Meat, and industry representative HollandBIO, has successfully developed a ‘code of practice’ that will allow tastings in controlled environments.